- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2019-10-30 16:16:51
- Reporting Period:
- Accepted Time:
- 2019-10-30 16:16:51
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1510487||Principia Biopharma Inc.||PRNB||Pharmaceutical Preparations (2834)||263487603|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1752139||J. Daniel Becker||C/o Principia Biopharma Inc. |
220 E. Grand Avenue
South San Francisco CA 94080
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Common Stock||Acquisiton||2019-10-28||68,404||$33.41||603,404||No||4||P||Indirect||See Footnote|
|Common Stock||Acquisiton||2019-10-29||9,196||$33.98||612,600||No||4||P||Indirect||See Footnote|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
- Price represents the weighted average price of the shares purchased. The purchase price ranged from $32.66 to $33.65 per share. Upon request by the Commission staff, the Issuer or the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.
- Price represents the weighted average price of the shares purchased. The purchase price ranged from $33.50 to $34.00 per share. Upon request by the Commission staff, the Issuer or the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.